IPCA Laboratories at PPFCF

From WebNotes, a public knowledge base. Last updated . Reading time ~11 min.

Lead

IPCA Laboratories Limited is among the periodic pharmaceutical mid-cap holdings of the Parag Parikh Flexi Cap Fund (PPFCF). The position has appeared in PPFCF factsheet portfolio listings across multiple cycles, alongside other healthcare holdings such as Cipla at PPFCF.

The IPCA Laboratories thesis combines several elements of the broader PPFAS investment philosophy. First, specialty therapy-area leadership: IPCA has historically been one of India’s largest manufacturers of anti-malarial active pharmaceutical ingredients (APIs) and formulations and has built strong franchises in cardiovascular, pain management and rheumatology. Second, generics and branded formulations mix: the company operates a balanced revenue mix across regulated-market generics exports, semi-regulated and emerging markets and Indian branded formulations. Third, disciplined valuation-driven entry: the team has typically built or added to the position during cyclical compression windows.

The position is also a useful illustration of PPFAS value investing applied to a mid-cap pharma franchise with regulatory exposure. IPCA has faced US FDA inspection issues at certain facilities in the past, with consequent restrictions on US exports from those plants. The team has looked through these issues during compression phases and held the position based on the broader franchise.

This article documents IPCA’s role in PPFCF: the company background, the investment thesis articulated by Rajeev Thakkar and Raunak Onkar, the position history across multiple factsheet cycles, recent positioning, and the comparison with peer holdings.

Company background

IPCA Laboratories Limited was incorporated in 1949 and operates as a fully integrated pharmaceutical company manufacturing both active pharmaceutical ingredients (APIs) and finished dosage forms. The company is headquartered in Mumbai and operates manufacturing facilities across India for both APIs and formulations.

IPCA is among India’s largest manufacturers of anti-malarial APIs (artemether, lumefantrine, chloroquine, hydroxychloroquine and others) and corresponding formulations. The company supplies anti-malarials to public-health institutions including the Global Fund and various country governments. Beyond anti-malarials, IPCA has built strong franchises in cardiovascular (beta-blockers, ACE inhibitors and other categories), pain management (NSAIDs and analgesics), rheumatology and dermatology.

The company’s revenue mix spans India formulations (branded prescription business), generics exports to regulated markets (US, UK, Europe), API exports, and semi-regulated and emerging markets exports. The Indian branded formulations business has been one of the higher-margin revenue streams.

The company’s equity shares are listed on the National Stock Exchange and the Bombay Stock Exchange and are part of the Nifty 500 TRI. The official corporate website is ipca.com (and the historical IPCA Laboratories portal at ipcalabs.com). The registered office is at Mumbai.

For Indian retail investors, exposure to IPCA is straightforward through direct equity purchase on the NSE/BSE or through diversified equity mutual fund schemes. PPFCF’s exposure delivers indirect ownership through a SEBI Mutual Funds Regulations 1996 registered scheme.

Investment thesis at PPFCF

The PPFAS thesis on IPCA Laboratories has been articulated across monthly factsheets and at the PPFAS Annual Unitholders Meet. The argument rests on several pillars.

First, PPFAS margin of safety. IPCA’s price-to-earnings multiple has compressed in cyclical periods, especially during phases of US FDA inspection concerns and US-exports constraints, providing valuation-driven entry windows.

Second, anti-malarial leadership. IPCA is among the world’s largest suppliers of anti-malarial APIs and formulations. The Global Fund and various government public-health programmes are important customers. While anti-malarial volumes can be lumpy, the franchise provides a durable revenue stream and competitive position.

Third, branded formulations strength. IPCA’s Indian branded prescription business across cardiovascular, pain management, rheumatology and other categories provides high-margin and growing revenue. The Indian formulations market has been a higher-quality end-market than US generics.

Fourth, vertical integration. IPCA’s manufacturing capabilities span APIs and formulations, supporting cost competitiveness and supply-chain control. The integration also positions IPCA for emerging therapeutic areas where API supply is critical.

Fifth, PPFAS focused portfolio discipline. IPCA meets the team’s quality bar through its specialty franchise, India formulations business and balance-sheet management.

Position history

IPCA Laboratories has appeared in PPFCF disclosures across multiple periods. The position has been mentioned in PPFCF factsheet portfolio listings as one of the recurring Indian holdings within the pharmaceutical cluster, alongside Cipla.

Through the 2018 to 2022 window the position fluctuated with pharma-sector cycles and IPCA-specific regulatory developments. The COVID-19 pandemic produced a temporary boost to hydroxychloroquine demand. The 2022 onwards period saw continued operational improvement and progressive resolution of historic FDA inspection issues at certain facilities.

The February 2022 SEBI MF overseas investment cap freeze created a structural pivot in which domestic positions received continued allocations.

By 2025 and into 2026 the position continued as a periodic significant holding within the broader PPFCF portfolio, though it did not enter the top three (which by April 2026 was HDFC Bank at PPFCF, Power Grid Corporation at PPFCF and Coal India at PPFCF).

Recent positioning

The April 2026 factsheet, with PPFCF AUM at Rs 1,40,949 crore (up 9.29 per cent month-on-month from Rs 1,28,966 crore in March 2026), continued to include IPCA within the recurring domestic holdings list. The May 2026 commentary on PPFCF carrying around 18 to 22 per cent in PPFAS cash holdings reflected broader valuation caution.

In monthly factsheet commentary, Rajeev Thakkar and Raunak Onkar have referenced IPCA’s anti-malarial franchise, the India formulations growth and operational improvement as supports for continued holding.

Comparison with peer holdings

Within PPFCF’s pharmaceutical cluster, IPCA sits alongside Cipla at PPFCF. Compared with Cipla, IPCA provides mid-cap operational beta and differentiated therapy-area exposure (anti-malarial leadership, cardiovascular strength) versus Cipla’s respiratory and US-generics focus. IPCA’s revenue mix is more weighted toward India formulations and emerging-markets exports.

Compared with ITC at PPFCF, IPCA offers different end-market exposure (regulated pharma versus FMCG). Compared with the banking cluster (HDFC Bank, ICICI Bank, Kotak Mahindra Bank at PPFCF), IPCA provides healthcare exposure that is uncorrelated with the Indian credit cycle.

Compared with international anchors Alphabet at PPFCF, Microsoft at PPFCF, Amazon at PPFCF and Meta Platforms at PPFCF, IPCA provides healthcare exposure that is uncorrelated with US-technology platform dynamics.

Within the broader PPFAS focused portfolio framework, IPCA is grouped with the banking cluster, the technology cluster (Infosys at PPFCF, TCS at PPFCF, HCL Technologies at PPFCF, Persistent Systems at PPFCF), the consumer-discretionary cluster (Maruti Suzuki at PPFCF, Mahindra and Mahindra at PPFCF, Bajaj Holdings at PPFCF) and the PSU contrarian positions as anchor Indian holdings.

Context within PPFCF

PPFCF was launched on 24 May 2013 as Parag Parikh Long Term Value Fund (PPLTVF), renamed Parag Parikh Long Term Equity Fund on 16 February 2018 and renamed Parag Parikh Flexi Cap Fund on 13 January 2021. The scheme is benchmarked against the Nifty 500 TRI and has delivered a compound annual growth rate since inception of approximately 19.06 per cent against a category average of 15.22 per cent and the Nifty 500 TRI at 12.4 per cent. AUM crossed Rs 1 lakh crore in May 2025, making PPFCF the first active equity mutual fund scheme in India to do so, and rose to roughly Rs 1.6 lakh crore by 15 May 2026.

The fund is managed by Rajeev Thakkar along with Raunak Onkar, Raj Mehta, Rukun Tarachandani and other team members. Parag Parikh, the founder of the Parag Parikh Financial Advisory Services Limited sponsor entity, established the investing house in 1979 and incorporated PPFAS Ltd in December 1992. The mutual fund was set up with SEBI on 10 October 2012 under registration ID MF/069/12/01.

IPCA Laboratories has been a recurring topic at the PPFAS Annual Unitholders Meet. The 12th edition was held on 22 November 2025 at Birla Matushree Sabhaghar in Mumbai.

See also

External references

References

  1. PPFAS Mutual Fund, October 2025 factsheet, amc.ppfas.com.
  2. PPFAS Mutual Fund, March 2026 factsheet, amc.ppfas.com.
  3. INDmoney, “PPFAS Flexi Cap April 2026 portfolio update,” indmoney.com.
  4. Angel One, “Parag Parikh Flexi Cap Fund crosses one lakh crore AUM,” angelone.in.
  5. Business Today, May 2026 cash commentary, businesstoday.in.
  6. IPCA Laboratories Limited, Annual Report 2024-25, ipca.com.
  7. Indian Pharmaceutical Alliance sector data.

Reviewed and published by

WebNotes Editorial Team

The WebNotes Editorial Team covers Indian capital markets, payments infrastructure and retail investor procedures. Every article is fact-checked against primary sources, principally SEBI circulars and master directions, NPCI specifications and the official support documentation published by the intermediary in question. Drafts go through a second-pair-of-eyes review and a separate compliance read before publication, and revisions are tracked against the SEBI and NPCI rule changes referenced in the methodology section.

Last reviewed
Conflicts of interest
WebNotes is independent. No relationship with any broker, registrar or bank named in this article.